Compare ARK Genomic Revolution ETF (ARKG) vs Garmin Ltd. (GRMN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Garmin Ltd. — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Garmin Ltd. trades at $242.7 (market cap $46.89B). The key difference: Garmin Ltd. pays a 1.73% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Garmin Ltd. nearer its low. Which is the better fit depends on your goals.
| ARKG | GRMN | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $267.52 |
52-Week Low | $23.09 | $187.10 |
Market Cap | — | $46.89B |
Enterprise Value | — | $44.35B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Garmin (GRMN) trades at $243.11, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company shows strong fundamentals with 2025 revenue of $7.25B and net income of $1.66B, maintaining robust profitability margins. Recent product launches in aviation and marine electronics highlight ongoing innovation. The stock is near its consensus price target of $282.67, indicating potential upside from current levels.
The outlook for GRMN remains positive driven by consistent earnings beats and dividend stability, though valuation multiples appear elevated. Key risks include competitive pressures in consumer electronics and reliance on discretionary spending. Analyst sentiment is cautious with 74% hold ratings, suggesting balanced risk-reward near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →
